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Abbreviations 
ADP: adenosine diphosphate 
AMP: adenosine monophosphate 
ANOVA: analysis of variance 
AoP: aortic pressure  
ATP: adenosine triphosphate  
CO: cardiac output 
CVP: central venous pressure  
DCD: donation after cardiac death 
ELISA: enzyme-linked immunosorbent assay  
IL: interleukin 
LAP: left atrial pressure  
PIP: peak inspiratory pressure  
PAP: pulmonary artery pressure  
ROS: reactive oxygen species 
RPL19: ribosomal protein L19  
TNF: tumor necrosis factor 
TUNEL: terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling 
WDR: wet-to-dry weight ratio  
WIT: warm ischemic time
Background: One method of countering chronic lung donor shortages is the practice of donation 
after cardiac death (DCD). However, this technique inevitably leads to pulmonary dysfunction 
related to warm ischemia. One promising method of alleviating this problem is ventilation. However, 
it can rarely be initiated from the onset of cardiac arrest, particularly in uncontrolled DCD donors. 
Here, we investigated the protective effect of the last 60 min of ventilation during a 240-min warm 
ischemic time. Methods: We rendered donor dogs cardiac-dead and left them at room temperature. 
Six dogs received ventilation with 100% oxygen for 60 min starting at 180 min after cardiac arrest 
(ventilation group). Eight dogs received no ventilation. Lungs were harvested 240 min after cardiac 
arrest, then transplanted into recipient dogs. At 60 min after reperfusion, the right pulmonary artery 
was ligated and the function of the left transplanted lung was evaluated. Results: In the ventilation 
group, all 6 animals survived for 240 min after reperfusion, while in the non-ventilation group, only 4 
out of 8 survived. The ventilation group demonstrated significantly better pulmonary oxygenation, 
shunt fraction, and wet-to-dry weight ratio. Furthermore, the ventilation group revealed significantly 
higher levels of high-energy phosphates in the lung tissues, fewer apoptotic cells, lower levels of 
TNF-α and IL-8 mRNA in the lung tissues, and lower levels of IL-6 mRNA in the serum. 
Conclusion: Our results suggest that ventilation during the late phase of the pre-procurement 





Lung transplantation is currently the definitive treatment of end-stage respiratory disease. However, 
it is limited by a shortage of suitable donors. One potential solution to this problem is donation after 
cardiac death (DCD). Indeed, more than 100 cases of lung transplantations from DCD donors have 
been reported, at least 28 of which involved uncontrolled DCD donors (1).  
Lung transplantation from DCD donors is feasible in part because the lung has a unique 
tolerance for ischemia; this is because lung cells are able to maintain aerobic metabolism by 
utilizing the oxygen in the alveoli even without perfusion (2). Some reports have already revealed 
that the lungs can be protected by inflation (2-4) or ventilation with oxygen (4,5). For instance, a 
continuous 240-min ventilation and heparin use before cardiac arrest attenuated lung injury 
induced by 240-min of WIT in a canine transplantation model (5).  
Although ventilation during the whole WIT is preferable, it is rarely possible to commence 
ventilation soon after cardiac arrest particularly in uncontrolled DCD donor. In order to determine 
the optimal technique for utilizing lungs from an uncontrolled DCD donor, we evaluated the 
protective effects of ventilation during the last 60 min of a 240-min WIT in a canine lung 
transplantation model. This simulates a situation commonly encountered in clinical practice—a 
non-heparinized, uncontrolled DCD donor receiving ventilation during the last period of WIT.  
 
Results     
There were no significant differences between the treatment groups in donor or recipient weight 
(ventilation group vs. non-ventilation group, donor weight: 10.4 ± 0.2 vs. 10.1 ± 0.4 kg; recipient 
weight: 9.5 ± 1.0 vs. 9.0 ± 0.4 kg), or in total ischemic time (ventilation group vs. non- ventilation 
group: 422.8 ± 9.2 vs. 430.0 ± 6.7 min). We set 60 min for the implantation time in our protocol and 
could perform within 60 min. All 6 animals in the ventilation group survived until the end-point of the 
study (240 min after reperfusion), while only half (4/8) of the non- ventilation group survived. All 4 
dead animals expired as the result of a graft dysfunction; 3 of the deaths occurred between 75 and 
120 min after reperfusion, while the fourth occurred between 120 and 180 min after reperfusion. 
 
Assessment of lung function  
PaO2 at 240 min after reperfusion was 619.5 ± 49.1vs. 204.5 ± 190.8 mmHg (ventilation group vs. 
non-ventilation group). Furthermore, by repeated analysis of variance between groups, both PaO2 
and pulmonary shunt fraction were significantly better in the ventilation group than in the 
non-ventilation group (P = 0.0057 and P = 0.010, respectively; Table 1). Peak airway pressure was 
higher in the non-ventilation group, but this difference did not reach significance (P = 0.072, Table 
1). Pulmonary artery pressure and pulmonary vascular resistance seemed high in the ventilation 
group, but these differences did not reach significance (P = 0.27 and P = 0.33, respectively; Table 
1)..  
 
Wet-to-dry lung weight ratio  
WDR at 240 min after reperfusion was significantly lower in the ventilation group than in the 
non-ventilation group (5.43 ± 0.67 vs. 8.06± 1.45, respectively; P = 0.010). 
 
Measurement of adenine nucleotide levels 
In the ventilation group, ATP levels and energy charge were significantly improved by the 60-min 
ventilation (P = 0.0090; Table 2B), though the improvements did not reach the levels observed in 
the normal lungs (Table 2A). Moreover, at 240 min after reperfusion, ATP and TAN (TAN = ATP + 
ADP +AMP) levels were significantly higher in the recipient lungs of ventilation group than in the 
recipient lungs of the non-ventilation group (P = 0.019 and 0.011, respectively; Table 2C) and the 
ATP and TAN levels improved similarly to those in the normal lungs (Table 2A),  
 
Macroscopic figures and histology 
At 240 min after reperfusion, lungs from the non- ventilation group had dark-red areas exhibiting 
more patchiness than was observed in the ventilation group macroscopically (Figures 1A and 1C). 
The histological study indicated severe intraparenchymal hemorrhage and inflammation. (Figure 
1B). 
 
In situ apoptosis detection 
At 240 min after reperfusion, there were significantly more TUNEL-positive cells in the 
non-ventilation group than in the ventilation group (P = 0.0019; Figure 2). This indicates that 
significantly more apoptosis occurred in the non-ventilation group. 
 
Serum cytokine levels 
At 75 min after reperfusion, TNF-α and IL-8 mRNA levels were significantly higher in the 
non-ventilation group than in the ventilation group (P = 0.0027 and P = 0.032, respectively; Figure 
3A, D). Likewise, at 240 min after reperfusion, serum IL-6 levels were significantly higher in the 
non-ventilation group than in the ventilation group (P = 0.011; Figure 3F ).  
 
Discussion 
In the present study, we used a canine lung transplantation model to evaluate the protective effect 
of ventilation during “only the last 60 min” of a 240-min WIT, while the previous studies revealed the 
protective effect of continuous ventilation in the whole WIT (5,6). Our results indicated that the last 
60 min of ventilation could preserve the lung function of an uncontrolled DCD donor. To be more 
specific, we observed better oxygenation, pulmonary shunt fraction, and wet-to-dry weight ratios in 
the ventilation treatment group. Furthermore, the ventilation group experienced significantly higher 
energy levels, better pathological findings, lower apoptosis, and lower levels of inflammatory 
cytokines. 
The mechanism by which the 60-min ventilation provides protection can be inferred from 
our measurements of adenine nucleotide levels, apoptosis, and inflammatory cytokines. First, the 
adenosine nucleotide levels recorded here suggest that ventilation increased energy charge and 
ATP levels in the donor lungs, as well as ATP and TAN levels in the recipients. Previously, 
increased TAN levels have been significantly associated with lung viability (7). In non-ventilated or 
nitrogen-ventilated lungs retrieved 4 hours after death, 50% of the pulmonary parenchymal cells in 
alveolar areas of the lung were dead. However, oxygen ventilation in WIT resulted in attenuation of 
cell death: Viability was observed in more than 90% of cells in oxygen-ventilated lungs retrieved 4 
hours after death and in 75% of cells from oxygen-ventilated lungs retrieved12 hours after arrest. 
Furthermore, depletion of ATP causes a decrease in the membrane potential of mitochondria (8), 
allowing calcium to escape and trigger the apoptotic process (9).  
Second, we found significantly fewer apoptotic cells in the ventilation group, which we 
believe may have resulted in better pulmonary function after the transplant. Previous studies have 
produced conflicting evidence as to whether apoptotic cells have a deleterious impact on organ 
function. When the apoptotic cascade is blocked, injured cells may not always recover, leading to 
necrosis that is injurious to surrounding tissue (10). However, previous studies have shown a 
reduction in ischemia-reperfusion injury of kidney, heart and lung after injection of antiapoptotic 
agents prior to reperfusion (11-13). Furthermore, it has been suggested that, in human lung 
transplantation, apoptosis may contribute to ischemia-reperfusion injury during the early phase of 
graft reperfusion and may be responsible for severe organ dysfunction (14).   
Third, we observed significant decreases in the mRNA levels of the inflammatory cytokines 
TNF-α, IL-8, and IL-6. Both anti- and pro-inflammatory cytokines, such as TNF-α, interferon-γ, IL-1β, 
IL-2, IL-6, IL-8, 1L-9, and IL-10, are known to be released in response to lung ischemia reperfusion 
injuries (15-17). The characteristics of the early phase of ischemia-reperfusion injury depend on 
donor macrophages, which release IL-8, 12, 18, TNF-α, and IFN-γ (15). IL-8 in particular seems to 
influence graft failure after human lung transplantation (18,19). Additionally, plasma levels of IL-6, 
IL-8, and TNF-α have been found to relate to endothelial dysfunction among apnea patients (20). 
Thus, in our study, it appears likely that the 60-min ventilation reduces donor macrophage 
activation and/or cytokine elevation in donor ischemic and non-ventilated lungs, thereby 
ameliorating endothelial dysfunction and the early phase of ischemia-reperfusion injury.  
Ventilation with 100% oxygen is a double-edged sword. For instance, it may be toxic if 
performed beyond 6 hours (4). Further, a comparison of ventilation with room air, oxygen, and 
nitrogen revealed that ischemia-reperfusion injury in oxygen-ventilated animals was aggravated by 
oxygen free radicals (21). Other studies have reported that free radical scavengers such as 
superoxide dismutase can have protective effects against pulmonary ischemia-reperfusion injuries 
(22). Though we did not examine oxygen free radicals, we did find relatively high levels of 
pulmonary artery pressure and pulmonary vascular resistance in the ventilation group, which may 
have resulted from the activity of free radicals. In DCD donors ventilated with high-concentration 
oxygen, free radical scavengers may improve the outcomes. On the other hand, Fisher et al. found 
that hypoxia in alveoli resulted in a sharp decrease in ATP and a corresponding increase in the ATP 
degradation product hypoxanthine, which generates superoxide when oxygen is reintroduced via 
reperfusion and/or ventilation (23); this is consistent with our observations in the non-ventilation 
group. Reactive oxygen species (ROS) are generated with a decrease in the membrane potential 
of mitochondria which results from the ATP degradation (9). Therefore, we hypothesize that 
hypoxia-induced superoxide accumulation was responsible for the poor results observed in the 
non-ventilation group in our study. Moreover, from a clinical point of view, oxygen ventilation is used 
to simulate uncontrolled DCD donors—cardiopulmonary-resuscitation patients, in particular. 
American Heart Association guidelines call for the use of 100% oxygen during cardiopulmonary 
resuscitation (24).  
Other protective methods for uncontrolled DCD donors include in situ topical cooling 
(25-27), which was reported to have superior protection compared to ventilation (28). However, 
ventilation is much easier and can be combined with medication, such as β-adrenergic agonists 
(29,30), nitric oxide (31), and isoflurane (32) delivered through the airway. Cardiac arrest patients 
are usually ventilated during cardiopulmonary resuscitation; even if their lives cannot be saved, this 
technique has the added benefit of preparing their lungs for possible transplantation, the functions 
of which are estimated via ex vivo lung perfusion (33,34), thus enlarging the donor pool.    
One limitation of our study is that it has not investigated how long we could extend the WIT 
period with the final 60-min ventilation. Additionally, because we focused only on 60-min 
ventilations, we were not able to ascertain whether shorter ventilation periods would be adequate 
for preserving lung function. Additionally, our evaluation of the ventilated lungs was limited to 240 
min after reperfusion. Finally, our study does not entirely mimic the clinical scenario in 
uncontrolled DCD donors in the following three points (35). First, these donors are ventilated within 
30 min after cardiac arrest. Second, topical cooling is performed after declaration of death. Third, 
there is agonal phase leading to inflammation in the lungs prior to cardiac arrest. Further research 
will explore each of these remaining questions. 
In conclusion, we found that the protective effect of ventilation during the last 60 min of a 
240-min WIT preserves lung function of uncontrolled DCD donors. Thus, use of the ventilation 
during this period may improve our ability to manage uncontrolled DCD donors, thus increasing 
lung donor utilization. 
 
Materials and Methods 
Animals 
Fourteen pairs of weight-matched TOYO Beagles (8.35-11.9 kg, Kitayama Labes Co. Ltd., Hongo 
Farm, Yamaguchi, Japan) were used in this study. All animals received humane care in compliance 
with the Principles of Laboratory Animal Care, formulated by the National Society for Medical 
Research, and the Guide for the Care and Use of Laboratory Animals, prepared by the Institute of 
Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication 
No. 86-23, revised 1996). The study protocol was approved by the ethics committee of the 
Graduate School of Medicine at Kyoto University, Japan. 
 
Donor preparation 
Donor dogs were anesthetized via an intramuscular injection of midazolam (0.5 mg/kg), xylazine 
(0.25 mg/kg), and atropine sulfate (0.05 mg/kg). They were then intubated and mechanically 
ventilated at a tidal volume of 25 ml/kg and a rate of 15 breaths/min. The positive end-expiratory 
pressure was 5.0 cm H2O; the inspired O2 fraction was 1.0. The donors were maintained at an 
inhalation of 1% to 2% sevoflurane and an intravenous injection of vecuronium bromide (0.4 
mg/kg/hr) and buprenorphine hydrochloride (0.01 mg/kg/hr). They were euthanized via an 
intravenous administration of potassium chloride (0.5 mEq/kg), without heparinization. The 
ventilators were removed and the tracheal tubes were open to room air. All donors were left at room 
temperature (21°C) for 240 min. The ventilation group (n = 6) received ventilation with 100% 
oxygen for 60 min starting at 180 min after cardiac arrest. The non-ventilation group (n = 8) did not 
receive any ventilation for 240 min after cardiac arrest. A pulmonary arterial flush was performed on 
all donors at 240 min after the cardiac arrest, using ET-Kyoto solution (Otsuka Pharmaceutical 
Factory Inc, Tokushima, Japan), an extracellular preservation solution that we originally developed 
for clinical lung transplantation (36,37). Prior to use, the ET-Kyoto solution was stored at 4°C. For 
the antegrade flush, we used 100 ml/kg; 50 ml/kg was used for the retrograde flush. Both were 
performed from 30 cm above the donors’ chests. Ventilation was performed during the flush. The 
harvested organs, semi-inflated (within 20 cm H2O) with 100% oxygen, were preserved at 4°C for 
120 min.  
 Recipient preparation and transplantation 
Recipient dogs were anesthetized, maintained, and ventilated in the same manner as the donors. 
Peak inspiratory pressure (PIP) was monitored by a pressure transducer that was attached to the 
tracheal tube. For each recipient, a 5F thermodilution catheter (151F7, Edwards Lifesciences, 
Irvine, CA, USA) was placed in the main pulmonary artery from the right femoral vein to measure 
pulmonary artery pressure (PAP), central venous pressure (CVP), and cardiac output (CO). A 
femoral arterial line was inserted for measuring aortic pressure (AoP) and for arterial blood gas 
analysis. After thoracotomy, a 2.0-mm catheter was inserted directly into the left atrium for 
monitoring left arterial pressure (LAP). We then performed a left pneumonectomy and left lung 
transplantation. We set 60 min for the implantation time The right pulmonary artery was encircled 
with a vascular tape and clamped with a tourniquet at 60 min after reperfusion in order to evaluate 
the function of the transplanted left lung. 
 
Pulmonary shunt fraction  
Pulmonary shunt fraction (Qs / Qt (%)) was calculated according to the following formula: [Qs/Qt 
(%) = (Cc – Ca)/(Cc – Cv) × 100], where Cc, Ca, and Cv represent the oxygen content of the 
pulmonary capillary blood, the pulmonary artery blood, and the pulmonary venous blood, 
respectively. 
 
Assessment of lung and cardiac function  
Arterial and pulmonary arterial blood samples were taken in order to analyze blood gases with a 
blood gas analyzer (iSTAT Portable Clinical Analyzer, iSTAT Corp., East Windsor, NJ, USA). 
 
Wet-to-dry lung weight ratio 
Left lung tissues (100-300 mg) were used to calculate the wet-to-dry weight ratio (WDR) at 240 min 
after reperfusion or at death. The tissues were excised from the tip of the lung and the cut end was 
closed by ligation. Wet weight (mg) was measured first; dry weight (mg) was measured after the 
tissue had been dried overnight at 180°C. The WDR was calculated by dividing the wet weight by 
the dry weight. 
 
Measurement of adenine nucleotide levels 
We used the pieces of peripheral lung tissues collected from “normal lungs”, which were collected 
from left lungs of recipients just after the anesthetic induction. Furthermore, we used ones from 
donors before and after ventilation and from the recipients at 240 min after reperfusion. We 
measured levels of adenosine triphosphate (ATP), adenosine diphosphate (ADP), and adenosine 
monophosphate (AMP) using high-performance liquid chromatography (Shim-pack CLC-ODS 
column; 15 cm × 6.0 mm; Shimadzu, Japan). Total adenosine nucleotides (TAN) and energy 
charge were calculated as previously reported (30).  
  
Macroscopic figures and histology (hematoxylin and eosin staining) 
We recorded the macroscopic appearances of the left lungs 240 min after reperfusion. Left lung 
specimens collected 240 min after reperfusion were used for histological analysis. Each lung was 
immersed in 10% formalin, embedded in paraffin, and stained with hematoxylin and eosin. 
 
In situ apoptosis detection (terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling 
(TUNEL) assay) 
An apoptosis in situ detection kit (Wako Jyunyaku, Osaka, Japan) was used to evaluate nick-end 
labeling of DNA fragmentation in paraffin-embedded sections of left lungs harvested at 240 min 
after reperfusion or death, as previously reported (38). TUNEL-positive cells were counted in 10 
randomly chosen high-power fields per section at an original magnification of 400×; apoptosis was 
expressed as the number of TUNEL-positive cells per section. Three separate investigators (J.S., 
F.C., and D.N.) evaluated, interpreted, and reached a consensus, without any knowledge of the 
experimental groups. 
 
Cytokine messenger RNA (mRNA) expression in lung tissues 
Left lung specimens collected at 75 min after reperfusion were stored in RNAlater TissueProtect 
tubes (Qiagen, Hiden, Germany) for RNA stabilization. Total RNA was extracted from specimens 
using an RNeasy Mini Kit (Qiagen), and the RNA extract was incubated with RNase-free DNase I 
(Qiagen) to remove contaminating DNA. Reverse transcription of total RNA was performed using 
Ready-To-Go You-Prime First-Strand Beads (GE Healthcare Bio-Sciences Corp, Piscataway, NJ, 
USA) to generate complementary DNA. We used oligonucleotide sequences originally described 
by Rachankonda et al. (39) and Koike et al. (40): interleukin (IL)-1β (39), IL-6 (39), IL-8 (39), tumor 
necrosis factor (TNF)-α (39), and ribosomal protein L19 (RPL19) (40). Quantitative real-time 
reverse-transcription polymerase chain reactions (qRT-PCR) were performed on a LightCycler 
using LightCycler FastStart DNA masterPLUS SYBR Green I mix (Qiagen). PCR conditions were 
as follows: initial denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 
30 s, annealing at 55°C for 30 s, and extension at 72°C for 30 s. Quantities of the genes of interest 
were calculated from corresponding standard curves using LIGHTCYCLER software (Roche, Basel, 
Switzerland); they are presented here in relation to the amount of RPL19.  
 
Serum cytokine levels 
We used enzyme-linked immunosorbent assays (ELISA) to measure serum IL-6, IL-8, and TNF-α 
levels at 240 min after reperfusion in surviving animals. In all cases, we followed the instructions in 
the manufacturer’s manuals from IL-6, IL-8, and TNF-α ELISA kits (Quantikine, R&D Systems Inc., 
Minneapolis, MN, USA).    
 
Statistical analyses 
All statistical analyses were performed using STATVIEW v5.0 (Abacus Concepts, Inc., Berkeley, 
CA, USA). Values are expressed as means ± standard deviations. We used Mann-Whitney U-tests 
and repeated-measures analysis of variance (ANOVA) tests to explore differences between and 
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Figure Legends 
Figure 1.  
Results of macroscopic (A, C) and histological (B, D) analyses conducted 240 min after reperfusion 
(hematoxylin-eosin staining, original magnification x 400). In the non-ventilation group, we 
observed many dark-red spots (A) and alveolar congestion, hemorrhage, infiltration, aggregation of 
inflammatory cells, and edema (B). However, the ventilation group looked relatively normal (C, D).  
 
Figure 2.  
TUNEL staining of lung sections harvested 240 minutes after reperfusion or death: (A) 
non-ventilation group; (B) ventilation group (original magnification x 400). Subjects in the 
non-ventilation group possessed significantly higher numbers of TUNEL-positive cell than subjects 
in the ventilation group (C). Data are presented as mean ± SD and were analyzed using a 
Mann-Whitney U-test. Non-Vent. = non-ventilation group; Vent. = ventilation group. 
 
Figure 3.  
Cytokine levels in the ventilation and non-ventilation groups at 2 different time points 
post-reperfusion. Cytokine messenger RNA (mRNA) expression in lungs at 75 min after 
reperfusion (A-D), with data normalized against ribosomal protein L19 (RPL19). mRNA expression 
of TNF-α and IL-8 was significantly higher in the non-ventilation group. Serum cytokine levels at 
240 min after reperfusion (E-G). Serum levels of IL-6 was significantly higher in the non-ventilated 
group. Data are presented as mean ± SD and were analyzed using a Mann-Whitney U-test. 
Non-Vent. = non-ventilation group; Vent. = ventilation group. 
Table 1.  Assessment of lung and cardiac function in surviving recipients in the non-ventilation (n = 4) and ventilation (n = 6) groups.  
    Time after transplantation, min 
 Before OP 0 30 75 120 180 240     P-value  
Mean AoP, mmHg  
Non-vent. 134.2 ± 18.5 130.5 ± 18.5 133.0 ± 22.0 115.2 ± 29.2 98.7 ± 28.7 95.2 ± 33.5 82.0 ± 28.0 
Vent. 130.6 ± 21.2 116.3 ± 17.8 116.0 ± 17.3 109.1 ± 22.4 105.1 ± 17.9 106.1 ± 23.6 95.5 ± 35.3 0.12 
Mean PAP, mmHg 
Non-vent. 17.5 ± 3.8 19.0 ± 3.5 19.7 ± 3.6 31.0 ± 11.9 33.5 ± 11.5 33.7 ± 16.3 32.5 ± 12.3 
Vent. 17.3 ± 2.1 19.1 ± 1.9 20.3 ± 2.9 39.3 ± 7.7 38.3 ± 6.2 40.0 ± 9.3 40.0 ± 9.4 0.27 
Mean CVP, mmHg 
Non-vent. 5.5 ± 1.2 6.7 ± 2.2 6.2 ± 2.2 8.7 ± 5.7 7.2 ± 2.7 8.7 ± 4.5 11.0 ± 7.6 
Vent. 5.5 ± 1.6 6.1 ± 1.1 6.0 ± 1.2 8.0 ± 1.2 8.0 ± 1.7 9.1 ± 2.3 8.6 ± 1.9 0.80 
Mean LAP, mmHg 
Non-vent. 13.5 ± 1.9 15.5 ± 2.5 15.5 ± 2.3 8.7 ± 1.2 7.7 ± 0.9 8.2 ± 1.7 9.0 ± 2.0 
Vent. 12.1 ± 1.4 11.3 ± 2.2 11.5 ± 3.5 8.3 ± 2.5 8.6 ± 4.4 9.3 ± 2.5 8.1 ± 2.9 0.35 
Cardiac output, l/min 
Non-vent. 0.8 ± 0.1 0.7 ± 0.0 0.8 ± 0.0 0.6 ± 0.1 0.7 ± 0.1 0.9 ± 0.2 0.8 ± 0.2 
Vent. 0.8 ± 0.1 0.7 ± 0.1 0.9 ± 0.2 0.7 ± 0.1 0.7 ± 0.1 0.8 ± 0.2 0.9 ± 0.4 0.82 
PVR, dyn･s･cm-5 x 103 
Non-vent. 382.2 ± 299.0 352.1 ± 329.6 431.1 ± 425.2 3160.1 ± 2057.2 2850.6 ± 1467.5 2416.9 ± 1617.2 2138.3 ± 1009.1  
Vent. 517.9 ± 265.1 883.6 ± 178.6 780.5 ± 281.9 3624.0 ± 1210.1 3281.8 ± 647.7 3018.1 ± 896.5 3105.0 ± 1269.8 0.33 
PaO2, mmHg 
Non-vent. 583.5 ± 63.6 565.2 ± 76.1 525.7 ± 172.4 404.7 ± 240.7 305.0 ± 267.4 268.7 ± 248.7 204.5 ± 190.8  
Vent. 595.1 ± 30.0 620.5 ± 42.3 637.1 ± 41.6 636.1 ± 32.8 642.5 ± 38.2 627.1 ± 25.6 619.5 ± 49.1 0.0057 
PaCO2, mmHg 
Non-vent. 21.1 ± 1.5 22.9 ± 4.2 23.2 ± 5.0 32.1 ± 6.0 43.3 ± 7.0 53.2 ± 9.4 60.4 ± 18.2 
Vent. 23.9 ± 4.6 22.6 ± 3.2 22.9 ± 3.0 33.8 ± 7.0 38.6 ± 7.9 37.6 ± 4.2 38.3 ± 6.3 0.12 
Peak airway pressure, mmHg 
Non-vent. 15.7 ± 2.5 14.7 ± 2.7 14.7 ± 2.7 19.0 ± 5.7 19.0 ± 4.9 20.0 ± 6.0 20.5 ± 5.4 
Vent. 15.1 ± 1.1 13.5 ± 1.3 12.8 ± 2.2 14.6 ± 1.0 14.1 ± 1.6 14.3 ± 1.0 14.6 ± 1.0 0.072 
Pulmonary shunt fraction, % 
Non-vent. 5.7 ± 3.8 7.7 ± 7.1 6.3 ± 3.4 10.3 ± 10.6 23.4 ± 26.8 28.6 ± 21.6 36.5 ± 27.9 
Vent. 6.3 ± 3.0 3.7 ± 2.2 2.5 ± 1.6 2.9 ± 2.8 2.1 ± 2.0 3.1 ± 4.0 3.4 ± 3.5 0.010 
OP = operation; AoP = aortic pressure; PAP = pulmonary artery pressure; CVP = central venous pressure; LAP = left atrial pressure; PVR = pulmonary vascular 
resistance. Data are shown as mean ± SD. P-values are for the differences between groups by repeated measures analysis of variance 
Table 2. Energy levels in normal lung (A), in donors before and after the 60-min ventilation (B), and in 
recipients at 240 min after reperfusion (C).  
A 
Energy levels  Normal lung  
ATP (nmol/mg･dw) 3.25 ± 0.66a   
Energy chargeb  0.73 ± 0.02   
TANc (nmol/mg･dw) 5.05 ± 0.73   
 
B 
Energy levels Before ventilation  After ventilation   P-value 
ATP  0.66 ± 0.11  1.71 ± 0.34  0.0090 
Energy charge 0.35 ± 0.03  0.63 ± 0.03  0.0090 
TAN  2.64 ± 0.35  3.19 ± 0.51  0.17 
 
C 
Energy levels  Ventilation group  Non-ventilation group P-value 
ATP  3.64 ± 0.50  2.52 ± 0.54  0.019 
Energy charge 0.82 ± 0.02  0.83 ± 0.03  0.52 
TAN  4.88 ± 0.55  3.33 ± 0.53  0.011 
 
aData are presented as mean ± SD and were analyzed with Mann-Whitney U-tests.  
bEnergy charge = (ATP + 0.5ATP) / (ATP + ADP + AMP).  
cTAN = ATP + ADP + AMP.  
ADP = adenosine diphosphate; AMP = adenosine monophosphate; ATP = adenosine triphosphate; 
TAN = total adenosine nucleotides. 
 
  
  
 
